Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia

Key Findings:  Resulting data suggest that pharmacological treatments with CB2 agonists (i.e. HU-308) may represent a novel treatment strategy in PD patients suffering from L-dopa induced dyskinesia (a relatively common and debilitating side-effect of the drug).

Type of Study:  Animal Study

Study Result:  Positive

Cannabinoids Studied:  HU-x Synthetic Cannabinoids

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB2

Study Location(s):  Australia

Year of Pub:  2020

Link to study